Business Context and Reporting Period
This Form 8-K Current Report was filed by Palisade Bio, Inc. on October 14, 2022, regarding events that occurred on October 11, 2022. The filing addresses significant changes in the company's executive leadership and board composition.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the compensation package for the departing CEO:
- Separation Payment: $530,000 payable in 12 equal monthly installments.
- Benefits: Up to 12 months of COBRA coverage and up to 6 months of virtual job-placement services valued at $3,100.
- Equity: Immediate vesting of all outstanding time-based option awards.
Material Changes
The primary material change reported is the departure of the Principal Executive Officer and a Board member:
- Resignation: Thomas Hallam, Ph.D., resigned as Chief Executive Officer and Board member effective October 11, 2022, to pursue other opportunities. The resignation was not related to any matter concerning the Company's operations, policies, or practices.
- Appointment: J.D. Finley, the current Chief Financial Officer, was appointed as Interim Chief Executive Officer effective October 11, 2022. He will continue to serve as CFO and principal accounting officer.
Outlook, Risks, and Management Commentary
The filing indicates a transition in leadership with no stated operational risks or contingencies related to the departure. Management commentary is limited to the confirmation that the separation was amicable and that the new interim CEO has extensive prior experience with the company, having served as CFO since April 2021 and as a board member of the predecessor company since December 2014. No forward-looking guidance or financial outlook is provided in this document.
Investor Verification Checklist
- Verify the terms of the Separation Agreement and Release (Exhibit 10.01) for any additional clauses not summarized in the text.
- Review the press release (Exhibit 99.01) for further details on the strategic rationale for the leadership change.
- Monitor subsequent filings for the appointment of a permanent CEO and any updates to the Board of Directors.
- Check the company's most recent 10-Q or 10-K for current liquidity and cash runway, as this 8-K does not contain financial statements.